-
公开(公告)号:US20240158368A1
公开(公告)日:2024-05-16
申请号:US18379351
申请日:2023-10-12
Applicant: AbbVie Inc.
Inventor: David A. Degoey , Michael R. Schrimpf , David J. Hardee , Jacob Ludwig , Eric R. Miller , Timothy R. Hodges , Alberto Munoz , Sarah J. Perlmutter , Huan-Qiu X. Li , Alvin Jang , Elizabeth L. Noey , Gregory A. Gfesser , Edgars Jecs , Robert G. Schmidt , Justin D. Dietrich , Xenia B. Searle , Boguslaw P. Nocek , Andrew Bogdan
IPC: C07D401/12 , A61P31/14
CPC classification number: C07D401/12 , A61P31/14
Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
-
公开(公告)号:US20180243298A1
公开(公告)日:2018-08-30
申请号:US15563888
申请日:2016-03-30
Applicant: AbbVie Inc.
Inventor: Lawrence Black , Brian S. Brown , Bruce Clapham , Marlon D. Cowart , Michael J. Dart , Ramin Faghih , Jennifer Frost , Arthur R. Gomtsyan , Philip R. Kym , Huaqing Liu , Robert G. Schmidt , Lei Shi , Anurupa Shrestha , Kevin Sippy
IPC: A61K31/506 , A61P17/06 , A61P17/04
CPC classification number: A61K31/506 , A61P17/04 , A61P17/06 , C07D417/12 , C07D417/14 , C07D491/048 , C07D491/107
Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
-
公开(公告)号:US20140080803A1
公开(公告)日:2014-03-20
申请号:US13658355
申请日:2012-10-23
Applicant: ABBVIE INC.
Inventor: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: A61K31/505 , A61K31/4418 , C07D213/34 , C07D213/38 , A61K31/444 , C07D239/26 , A61K31/4433 , C07D401/06 , A61K31/4427 , C07D405/08 , A61K31/443 , C07D417/08 , A61K31/4439 , A61K45/06 , A61K31/192 , C07D213/30
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式(I)的TRPV3的调节剂,其中p为1,2,3或4,并且G1,X1,X2,X3,X4,X5,G2,Z1,Ra,Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US20130131036A1
公开(公告)日:2013-05-23
申请号:US13658374
申请日:2012-10-23
Applicant: AbbVie Inc.
Inventor: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: A61K31/435 , A61K31/444 , C07D239/26 , A61K31/505 , C07D405/10 , A61K31/4433 , C07D405/06 , A61K31/443 , A61K31/4427 , C07D213/72 , C07D401/06 , A61K31/4545 , C07D215/14 , A61K31/47 , C07D221/04 , A61K31/4439 , A61K45/06 , C07D213/30
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式(II)的TRPV3的调节剂:其中G1,X1,X2,X3,X4,X5,G2,Ra,Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US08772500B2
公开(公告)日:2014-07-08
申请号:US13658374
申请日:2012-10-23
Applicant: AbbVie Inc.
Inventor: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt
IPC: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式(II)的TRPV3的调节剂:其中G1,X1,X2,X3,X4,X5,G2,Ra,Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US08772499B2
公开(公告)日:2014-07-08
申请号:US13658355
申请日:2012-10-23
Applicant: AbbVie Inc.
Inventor: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式(I)的TRPV3的调节剂,其中p为1,2,3或4,并且G1,X1,X2,X3,X4,X5,G2,Z1,Ra,Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
-
-
-
-